IL1A and COVID-19: Pooled analyses of RCTs testing anakinra use in COVID-19 have not shown benefit, and analysis of IL-1 concentrations in COVID-19 and in sepsis generally are inconsistent with a significant role for IL-1 in pathogenesis.